▶ 調査レポート

世界のCART細胞ベース医薬品市場(~2028年):CD19ターゲット、BCMAターゲット

• 英文タイトル:Global Drug based on CAR T-Cell Market Insights, Forecast to 2028

Global Drug based on CAR T-Cell Market Insights, Forecast to 2028「世界のCART細胞ベース医薬品市場(~2028年):CD19ターゲット、BCMAターゲット」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-19002
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、112ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品&医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、CART細胞ベース医薬品のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
CART細胞ベース医薬品のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
CART細胞ベース医薬品の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
CART細胞ベース医薬品のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までのCART細胞ベース医薬品の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のCART細胞ベース医薬品の売上および2028年までの予測に焦点を当てています。

CART細胞ベース医薬品のグローバル主要企業には、Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、CARsgen Therapeutics、Autolus Therapeutics、Sorrento Therapeutics、Mustang Bio、Bluebird Bio、Cellectis、Allogene Therapeutics、Celyadなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

CART細胞ベース医薬品市場は、タイプとアプリケーションによって区分されます。世界のCART細胞ベース医薬品市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
CD19ターゲット、BCMAターゲット

【アプリケーション別セグメント】
リンパ腫、多発性骨髄腫

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- CART細胞ベース医薬品製品概要
- タイプ別市場(CD19ターゲット、BCMAターゲット)
- アプリケーション別市場(リンパ腫、多発性骨髄腫)
- 調査の目的
・エグゼクティブサマリー
- 世界のCART細胞ベース医薬品販売量予測2017-2028
- 世界のCART細胞ベース医薬品売上予測2017-2028
- CART細胞ベース医薬品の地域別販売量
- CART細胞ベース医薬品の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別CART細胞ベース医薬品販売量
- 主要メーカー別CART細胞ベース医薬品売上
- 主要メーカー別CART細胞ベース医薬品価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(CD19ターゲット、BCMAターゲット)
- CART細胞ベース医薬品のタイプ別販売量
- CART細胞ベース医薬品のタイプ別売上
- CART細胞ベース医薬品のタイプ別価格
・アプリケーション別市場規模(リンパ腫、多発性骨髄腫)
- CART細胞ベース医薬品のアプリケーション別販売量
- CART細胞ベース医薬品のアプリケーション別売上
- CART細胞ベース医薬品のアプリケーション別価格
・北米市場
- 北米のCART細胞ベース医薬品市場規模(タイプ別、アプリケーション別)
- 主要国別のCART細胞ベース医薬品市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのCART細胞ベース医薬品市場規模(タイプ別、アプリケーション別)
- 主要国別のCART細胞ベース医薬品市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のCART細胞ベース医薬品市場規模(タイプ別、アプリケーション別)
- 主要国別のCART細胞ベース医薬品市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のCART細胞ベース医薬品市場規模(タイプ別、アプリケーション別)
- 主要国別のCART細胞ベース医薬品市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのCART細胞ベース医薬品市場規模(タイプ別、アプリケーション別)
- 主要国別のCART細胞ベース医薬品市場規模(トルコ、サウジアラビア)
・企業情報
Novartis、Gilead Sciences、Bristol-Myers Squibb、J & J、JW Therapeutics、FOSUNKite、CARsgen Therapeutics (Pipeline)、CARsgen Therapeutics、Autolus Therapeutics、Sorrento Therapeutics、Mustang Bio、Bluebird Bio、Cellectis、Allogene Therapeutics、Celyad
・産業チェーン及び販売チャネル分析
- CART細胞ベース医薬品の産業チェーン分析
- CART細胞ベース医薬品の原材料
- CART細胞ベース医薬品の生産プロセス
- CART細胞ベース医薬品の販売及びマーケティング
- CART細胞ベース医薬品の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- CART細胞ベース医薬品の産業動向
- CART細胞ベース医薬品のマーケットドライバー
- CART細胞ベース医薬品の課題
- CART細胞ベース医薬品の阻害要因
・主な調査結果

Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Drug based on CAR T-Cell estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Drug based on CAR T-Cell is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Drug based on CAR T-Cell is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Drug based on CAR T-Cell is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Drug based on CAR T-Cell include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Drug based on CAR T-Cell companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Drug based on CAR T-Cell market. Further, it explains the major drivers and regional dynamics of the global Drug based on CAR T-Cell market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Drug based on CAR T-Cell Segment by Type
CD19-targeted
BCMA-targeted
Drug based on CAR T-Cell Segment by Application
Lymphoma
Multiple Myeloma
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Drug based on CAR T-Cell market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Drug based on CAR T-Cell market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Drug based on CAR T-Cell, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drug based on CAR T-Cell, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug based on CAR T-Cell revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Drug based on CAR T-Cell market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Drug based on CAR T-Cell revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics and Autolus Therapeutics, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drug based on CAR T-Cell in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug based on CAR T-Cell companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug based on CAR T-Cell revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drug based on CAR T-Cell Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 CD19-targeted
1.2.3 BCMA-targeted
1.3 Market by Application
1.3.1 Global Drug based on CAR T-Cell Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lymphoma
1.3.3 Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drug based on CAR T-Cell Market Perspective (2017-2028)
2.2 Drug based on CAR T-Cell Growth Trends by Region
2.2.1 Drug based on CAR T-Cell Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Drug based on CAR T-Cell Historic Market Size by Region (2017-2022)
2.2.3 Drug based on CAR T-Cell Forecasted Market Size by Region (2023-2028)
2.3 Drug based on CAR T-Cell Market Dynamics
2.3.1 Drug based on CAR T-Cell Industry Trends
2.3.2 Drug based on CAR T-Cell Market Drivers
2.3.3 Drug based on CAR T-Cell Market Challenges
2.3.4 Drug based on CAR T-Cell Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drug based on CAR T-Cell Players by Revenue
3.1.1 Global Top Drug based on CAR T-Cell Players by Revenue (2017-2022)
3.1.2 Global Drug based on CAR T-Cell Revenue Market Share by Players (2017-2022)
3.2 Global Drug based on CAR T-Cell Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drug based on CAR T-Cell Revenue
3.4 Global Drug based on CAR T-Cell Market Concentration Ratio
3.4.1 Global Drug based on CAR T-Cell Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug based on CAR T-Cell Revenue in 2021
3.5 Drug based on CAR T-Cell Key Players Head office and Area Served
3.6 Key Players Drug based on CAR T-Cell Product Solution and Service
3.7 Date of Enter into Drug based on CAR T-Cell Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug based on CAR T-Cell Breakdown Data by Type
4.1 Global Drug based on CAR T-Cell Historic Market Size by Type (2017-2022)
4.2 Global Drug based on CAR T-Cell Forecasted Market Size by Type (2023-2028)
5 Drug based on CAR T-Cell Breakdown Data by Application
5.1 Global Drug based on CAR T-Cell Historic Market Size by Application (2017-2022)
5.2 Global Drug based on CAR T-Cell Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Drug based on CAR T-Cell Market Size (2017-2028)
6.2 North America Drug based on CAR T-Cell Market Size by Type
6.2.1 North America Drug based on CAR T-Cell Market Size by Type (2017-2022)
6.2.2 North America Drug based on CAR T-Cell Market Size by Type (2023-2028)
6.2.3 North America Drug based on CAR T-Cell Market Share by Type (2017-2028)
6.3 North America Drug based on CAR T-Cell Market Size by Application
6.3.1 North America Drug based on CAR T-Cell Market Size by Application (2017-2022)
6.3.2 North America Drug based on CAR T-Cell Market Size by Application (2023-2028)
6.3.3 North America Drug based on CAR T-Cell Market Share by Application (2017-2028)
6.4 North America Drug based on CAR T-Cell Market Size by Country
6.4.1 North America Drug based on CAR T-Cell Market Size by Country (2017-2022)
6.4.2 North America Drug based on CAR T-Cell Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Drug based on CAR T-Cell Market Size (2017-2028)
7.2 Europe Drug based on CAR T-Cell Market Size by Type
7.2.1 Europe Drug based on CAR T-Cell Market Size by Type (2017-2022)
7.2.2 Europe Drug based on CAR T-Cell Market Size by Type (2023-2028)
7.2.3 Europe Drug based on CAR T-Cell Market Share by Type (2017-2028)
7.3 Europe Drug based on CAR T-Cell Market Size by Application
7.3.1 Europe Drug based on CAR T-Cell Market Size by Application (2017-2022)
7.3.2 Europe Drug based on CAR T-Cell Market Size by Application (2023-2028)
7.3.3 Europe Drug based on CAR T-Cell Market Share by Application (2017-2028)
7.4 Europe Drug based on CAR T-Cell Market Size by Country
7.4.1 Europe Drug based on CAR T-Cell Market Size by Country (2017-2022)
7.4.2 Europe Drug based on CAR T-Cell Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drug based on CAR T-Cell Market Size (2017-2028)
8.2 Asia-Pacific Drug based on CAR T-Cell Market Size by Type
8.2.1 Asia-Pacific Drug based on CAR T-Cell Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Drug based on CAR T-Cell Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Drug based on CAR T-Cell Market Share by Type (2017-2028)
8.3 Asia-Pacific Drug based on CAR T-Cell Market Size by Application
8.3.1 Asia-Pacific Drug based on CAR T-Cell Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Drug based on CAR T-Cell Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Drug based on CAR T-Cell Market Share by Application (2017-2028)
8.4 Asia-Pacific Drug based on CAR T-Cell Market Size by Region
8.4.1 Asia-Pacific Drug based on CAR T-Cell Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Drug based on CAR T-Cell Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drug based on CAR T-Cell Market Size (2017-2028)
9.2 Latin America Drug based on CAR T-Cell Market Size by Type
9.2.1 Latin America Drug based on CAR T-Cell Market Size by Type (2017-2022)
9.2.2 Latin America Drug based on CAR T-Cell Market Size by Type (2023-2028)
9.2.3 Latin America Drug based on CAR T-Cell Market Share by Type (2017-2028)
9.3 Latin America Drug based on CAR T-Cell Market Size by Application
9.3.1 Latin America Drug based on CAR T-Cell Market Size by Application (2017-2022)
9.3.2 Latin America Drug based on CAR T-Cell Market Size by Application (2023-2028)
9.3.3 Latin America Drug based on CAR T-Cell Market Share by Application (2017-2028)
9.4 Latin America Drug based on CAR T-Cell Market Size by Country
9.4.1 Latin America Drug based on CAR T-Cell Market Size by Country (2017-2022)
9.4.2 Latin America Drug based on CAR T-Cell Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drug based on CAR T-Cell Market Size (2017-2028)
10.2 Middle East & Africa Drug based on CAR T-Cell Market Size by Type
10.2.1 Middle East & Africa Drug based on CAR T-Cell Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Drug based on CAR T-Cell Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Drug based on CAR T-Cell Market Share by Type (2017-2028)
10.3 Middle East & Africa Drug based on CAR T-Cell Market Size by Application
10.3.1 Middle East & Africa Drug based on CAR T-Cell Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Drug based on CAR T-Cell Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Drug based on CAR T-Cell Market Share by Application (2017-2028)
10.4 Middle East & Africa Drug based on CAR T-Cell Market Size by Country
10.4.1 Middle East & Africa Drug based on CAR T-Cell Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Drug based on CAR T-Cell Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Drug based on CAR T-Cell Introduction
11.1.4 Novartis Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.1.5 Novartis Recent Developments
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Details
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Drug based on CAR T-Cell Introduction
11.2.4 Gilead Sciences Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.2.5 Gilead Sciences Recent Developments
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Introduction
11.3.4 Bristol-Myers Squibb Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.3.5 Bristol-Myers Squibb Recent Developments
11.4 J & J
11.4.1 J & J Company Details
11.4.2 J & J Business Overview
11.4.3 J & J Drug based on CAR T-Cell Introduction
11.4.4 J & J Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.4.5 J & J Recent Developments
11.5 JW Therapeutics
11.5.1 JW Therapeutics Company Details
11.5.2 JW Therapeutics Business Overview
11.5.3 JW Therapeutics Drug based on CAR T-Cell Introduction
11.5.4 JW Therapeutics Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.5.5 JW Therapeutics Recent Developments
11.6 FOSUNKite
11.6.1 FOSUNKite Company Details
11.6.2 FOSUNKite Business Overview
11.6.3 FOSUNKite Drug based on CAR T-Cell Introduction
11.6.4 FOSUNKite Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.6.5 FOSUNKite Recent Developments
11.7 CARsgen Therapeutics (Pipeline)
11.7.1 CARsgen Therapeutics (Pipeline) Company Details
11.7.2 CARsgen Therapeutics (Pipeline) Business Overview
11.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Introduction
11.7.4 CARsgen Therapeutics (Pipeline) Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.7.5 CARsgen Therapeutics (Pipeline) Recent Developments
11.8 CARsgen Therapeutics
11.8.1 CARsgen Therapeutics Company Details
11.8.2 CARsgen Therapeutics Business Overview
11.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Introduction
11.8.4 CARsgen Therapeutics Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.8.5 CARsgen Therapeutics Recent Developments
11.9 Autolus Therapeutics
11.9.1 Autolus Therapeutics Company Details
11.9.2 Autolus Therapeutics Business Overview
11.9.3 Autolus Therapeutics Drug based on CAR T-Cell Introduction
11.9.4 Autolus Therapeutics Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.9.5 Autolus Therapeutics Recent Developments
11.10 Sorrento Therapeutics
11.10.1 Sorrento Therapeutics Company Details
11.10.2 Sorrento Therapeutics Business Overview
11.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Introduction
11.10.4 Sorrento Therapeutics Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.10.5 Sorrento Therapeutics Recent Developments
11.11 Mustang Bio
11.11.1 Mustang Bio Company Details
11.11.2 Mustang Bio Business Overview
11.11.3 Mustang Bio Drug based on CAR T-Cell Introduction
11.11.4 Mustang Bio Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.11.5 Mustang Bio Recent Developments
11.12 Bluebird Bio
11.12.1 Bluebird Bio Company Details
11.12.2 Bluebird Bio Business Overview
11.12.3 Bluebird Bio Drug based on CAR T-Cell Introduction
11.12.4 Bluebird Bio Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.12.5 Bluebird Bio Recent Developments
11.13 Cellectis
11.13.1 Cellectis Company Details
11.13.2 Cellectis Business Overview
11.13.3 Cellectis Drug based on CAR T-Cell Introduction
11.13.4 Cellectis Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.13.5 Cellectis Recent Developments
11.14 Allogene Therapeutics
11.14.1 Allogene Therapeutics Company Details
11.14.2 Allogene Therapeutics Business Overview
11.14.3 Allogene Therapeutics Drug based on CAR T-Cell Introduction
11.14.4 Allogene Therapeutics Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.14.5 Allogene Therapeutics Recent Developments
11.15 Celyad
11.15.1 Celyad Company Details
11.15.2 Celyad Business Overview
11.15.3 Celyad Drug based on CAR T-Cell Introduction
11.15.4 Celyad Revenue in Drug based on CAR T-Cell Business (2017-2022)
11.15.5 Celyad Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer